Letícia de Oliveira Marusso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Letícia de Oliveira Marusso has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander Brandão Santana
Universidade Federal de Alfenas
1 shared publication - Carla Speroni Ceron
Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Brazil
1 shared publication - Danielle Aparecida Ferreira de Oliveira Marrafon
Faculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, Brazil
1 shared publication - Jose Eduardo Tanus-Santos
Department of Pharmacology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil
1 shared publication - Jéssyca Milene Ribeiro
Department of Food and Drugs School of Pharmaceutical Sciences Federal University of Alfenas Rua Gabriel Monteiro da Silva 700 37130-001 Alfenas MG Brazil
1 shared publication - Larissa Helena Torres
Department of Food and Drugs, Faculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, MG, Brazil
1 shared publication
Latest Publications
- 28 January 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (6) , 6561-6577
Effectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review
Evidence suggests that sodium nitrite may be effective in the treatment of hypertension and pulmonary hypertension. However, its use remains debated due to safety concerns. In response, a scoping review was conducted to map current knowledge on the efficacy and safety of sodium nitrite in patients with hypertension or pulmonary hypertension, addressing the question: What evidence supports the effectiveness and safety of using sodium nitrite in these patients? The databases MEDLINE (PubMed), EMBASE, Scopus, Web of Science, and LILACS were searched for clinical studies on hypertensive patients at any disease stage without restrictions on age, sex, ethnicity, publication date, or status. The primary outcomes analyzed were the efficacy and safety of sodium nitrite. A total of nine articles were included, eight from databases and one from gray literature. Sample sizes ranged from 5 to 36 patients, with sodium nitrite doses between 240 µg/kg/h and 325 mg. Five studies showed positive results for treating essential hypertension. Regarding safety, only one study raised concerns about adverse effects, probably due to the high dose that was used. In pulmonary hypertension patients classified as groups 2, 3, and 5, four studies suggested sodium nitrite was effective and safe, but it was ineffective in group 1. The studies included several significant limitations that should be considered. As such, the current evidence is insufficient to definitively confirm the efficacy and safety of sodium nitrite in hypertensive patients. Further research with larger sample sizes is necessary to obtain more conclusive results.
- 28 January 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (6) , 6561-6577
Effectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review
Evidence suggests that sodium nitrite may be effective in the treatment of hypertension and pulmonary hypertension. However, its use remains debated due to safety concerns. In response, a scoping review was conducted to map current knowledge on the efficacy and safety of sodium nitrite in patients with hypertension or pulmonary hypertension, addressing the question: What evidence supports the effectiveness and safety of using sodium nitrite in these patients? The databases MEDLINE (PubMed), EMBASE, Scopus, Web of Science, and LILACS were searched for clinical studies on hypertensive patients at any disease stage without restrictions on age, sex, ethnicity, publication date, or status. The primary outcomes analyzed were the efficacy and safety of sodium nitrite. A total of nine articles were included, eight from databases and one from gray literature. Sample sizes ranged from 5 to 36 patients, with sodium nitrite doses between 240 µg/kg/h and 325 mg. Five studies showed positive results for treating essential hypertension. Regarding safety, only one study raised concerns about adverse effects, probably due to the high dose that was used. In pulmonary hypertension patients classified as groups 2, 3, and 5, four studies suggested sodium nitrite was effective and safe, but it was ineffective in group 1. The studies included several significant limitations that should be considered. As such, the current evidence is insufficient to definitively confirm the efficacy and safety of sodium nitrite in hypertensive patients. Further research with larger sample sizes is necessary to obtain more conclusive results.